A biomarker can be accepted for a specified role in drug development. That acceptance has a defined scope and does not approve every test that measures it.
FDA biomarker qualification concerns a specified interpretation and context of use in medical product development. The agency explicitly distinguishes qualification of the biomarker from qualification of its measurement method. The biomarker, specimen source, measurable characteristic and analytic method belong in a complete description. A qualification claim should retain that scope rather than being treated as general diagnostic approval or proof of clinical utility for every use.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Analytical versus clinical validation, Evidence from measurement to patient benefit.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Evidence from measurement to patient benefit, Biomarker.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/